Centes­sa gives An­toine Yver a new role, brings his old col­league on board; Pre­lude to a change: Jane Huang sets up her next move

→ Centes­sa looked to Dai­ichi Sankyo to fill the CMO post with An­toine Yver back in May 2021, and now that Yver has gar­nered a new ti­tle, why mess with a good thing?

Yver has been in­stalled as chair­man of de­vel­op­ment, and Centes­sa is go­ing back to the En­her­tu well again by ap­point­ing Javad Shahi­di as CMO. While Yver was head of on­col­o­gy R&D at Dai­ichi Sankyo, Shahi­di was the glob­al team leader for En­her­tu at the As­traZeneca part­ner. “I look for­ward to work­ing with Javad again as we con­tin­ue to grow Centes­sa with this in­cred­i­ble port­fo­lio of as­sets and come clos­er to bring­ing im­pact­ful new med­i­cines to pa­tients,” Yver said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER